toggle visibility Search & Display Options

Select All    Deselect All
 |   | 
Details
   print
  Record Links
Author Bisgaard, H. url  doi
openurl 
  Title Effect of long-acting beta2 agonists on exacerbation rates of asthma in children Type Journal Article
  Year (down) 2003 Publication Pediatric Pulmonology Abbreviated Journal Pediatr Pulmonol  
  Volume 36 Issue 5 Pages 391-398  
  Keywords Administration, Inhalation; Adolescent; Adrenal Cortex Hormones/*administration & dosage; Asthma/*drug therapy/physiopathology; Child; Child, Preschool; Disease Progression; Drug Therapy, Combination; Hospitalization; Humans; Placebo Effect; Randomized Controlled Trials as Topic; Receptors, Adrenergic, beta-2/*administration & dosage; Risk Assessment; Treatment Outcome  
  Abstract The purpose of this analysis was to examine the effect of long-acting beta(2)-adrenoceptor agonists (LABAs) on the asthma exacerbation rate in pediatric patients. Randomized controlled trials (RCT) that included the use of LABAs to treat symptoms of pediatric asthma in children on inhaled corticosteroids, that reported asthma exacerbation rates, and that were published as full papers in peer-reviewed journals were retrieved from a search of the medical literature. Eight studies were identified that fulfilled these criteria. An exacerbation was defined as deterioration in a patient's asthma requiring a change in prescribed medication or not defined but reported as an asthma exacerbation or an asthma-related hospitalization. Analysis of data from the eight studies revealed no apparent protection from an asthma exacerbation among children on a LABA compared to patients on comparator treatment. The relative risk of an asthma exacerbation for LABA compared to placebo or short-acting beta(2)-adrenoceptor agonist (SABA) ranged from 0.95-1.86. The relative risk of hospitalization for asthma in patients treated with LABAs with regular maintenance with ICS ranged from 3.3-21.6 in the three studies that reported asthma-related hospitalizations. The lack of evidence for the control of asthma exacerbations in children regularly using a LABA should bring into question its general use as add-on therapy. Studies should be designed to directly explore the implications of these observations in pediatric patients.  
  Address Copenhagen Studies on Asthma in Childhood (COPSAC), Department of Pediatrics, Copenhagen University Hospital, Amtssygehuset i Gentofte, Copenhagen, Denmark. Bisgaard@copsac.dk  
  Corporate Author Thesis  
  Impact Factor 02,704 First Author Bisgaard, H. Editor  
  Language English Summary Language Original Title  
  Series Editor Series Title Abbreviated Series Title  
  Series Volume Series Issue Senior Author Bisgaard, H.  
  ISSN 1099-0496 ISBN Medium  
  Area Expedition Conference  
  Notes PMID:14520721 Approved no  
  Call Number Serial 166  
Permanent link to this record
Select All    Deselect All
 |   | 
Details
   print

Save Citations:
Export Records: